Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 16 | 2025 | 453 | 3.090 |
Why?
|
| Vascular Diseases | 2 | 2025 | 151 | 0.950 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 4 | 2024 | 422 | 0.950 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2024 | 211 | 0.900 |
Why?
|
| Lung Diseases | 2 | 2025 | 396 | 0.860 |
Why?
|
| Lung | 4 | 2025 | 1522 | 0.680 |
Why?
|
| Actigraphy | 2 | 2024 | 47 | 0.420 |
Why?
|
| Infant, Newborn | 11 | 2026 | 8368 | 0.340 |
Why?
|
| Walk Test | 3 | 2025 | 30 | 0.320 |
Why?
|
| Hemodynamics | 3 | 2022 | 825 | 0.300 |
Why?
|
| Child, Preschool | 11 | 2026 | 14462 | 0.250 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 442 | 0.250 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2026 | 4 | 0.250 |
Why?
|
| Infant | 9 | 2026 | 12806 | 0.240 |
Why?
|
| Portal System | 1 | 2025 | 35 | 0.230 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 18 | 0.220 |
Why?
|
| Exercise Tolerance | 1 | 2025 | 87 | 0.220 |
Why?
|
| Vascular Malformations | 1 | 2025 | 107 | 0.210 |
Why?
|
| Registries | 1 | 2020 | 1539 | 0.200 |
Why?
|
| Walking | 1 | 2025 | 229 | 0.200 |
Why?
|
| Humans | 25 | 2026 | 127455 | 0.200 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2024 | 140 | 0.190 |
Why?
|
| Down Syndrome | 1 | 2025 | 204 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 322 | 0.180 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 200 | 0.180 |
Why?
|
| Exercise | 2 | 2024 | 845 | 0.180 |
Why?
|
| Echocardiography | 3 | 2024 | 1115 | 0.170 |
Why?
|
| Biopsy | 1 | 2024 | 1237 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2024 | 762 | 0.170 |
Why?
|
| Child | 12 | 2026 | 25296 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2024 | 552 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2025 | 6249 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2022 | 215 | 0.160 |
Why?
|
| Sildenafil Citrate | 2 | 2016 | 57 | 0.150 |
Why?
|
| Infant, Premature | 2 | 2023 | 826 | 0.150 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 143 | 0.150 |
Why?
|
| Phenotype | 2 | 2026 | 4309 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 145 | 0.140 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2007 | 6 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2017 | 31 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 357 | 0.130 |
Why?
|
| Hemophilia A | 1 | 2007 | 25 | 0.130 |
Why?
|
| Collateral Circulation | 1 | 2017 | 41 | 0.130 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 63 | 0.130 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2017 | 24 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2017 | 129 | 0.130 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 72 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 325 | 0.130 |
Why?
|
| Female | 14 | 2026 | 68733 | 0.130 |
Why?
|
| Premature Birth | 1 | 2021 | 404 | 0.130 |
Why?
|
| Prognosis | 3 | 2021 | 4803 | 0.130 |
Why?
|
| Angioplasty, Balloon | 1 | 2017 | 129 | 0.120 |
Why?
|
| Growth Differentiation Factors | 1 | 2016 | 12 | 0.120 |
Why?
|
| Male | 15 | 2026 | 62861 | 0.120 |
Why?
|
| Adolescent | 8 | 2026 | 20154 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3269 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 717 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2016 | 165 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2125 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2020 | 1011 | 0.110 |
Why?
|
| Hypotension | 1 | 2016 | 184 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1141 | 0.100 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 629 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 217 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 217 | 0.100 |
Why?
|
| Syndrome | 2 | 2026 | 1137 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 270 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17076 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2025 | 1406 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 459 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3720 | 0.080 |
Why?
|
| Mutation | 2 | 2020 | 5948 | 0.070 |
Why?
|
| Pregnancy | 1 | 2021 | 7423 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5160 | 0.060 |
Why?
|
| Survival Rate | 1 | 2020 | 2111 | 0.060 |
Why?
|
| Sample Size | 1 | 2024 | 84 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2025 | 359 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 2814 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 16 | 0.050 |
Why?
|
| Creatinine | 1 | 2024 | 385 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 592 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 49 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2026 | 808 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2017 | 581 | 0.050 |
Why?
|
| Heart Rate | 1 | 2024 | 573 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2024 | 799 | 0.040 |
Why?
|
| Time Factors | 2 | 2024 | 6169 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 489 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 69 | 0.040 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 33 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1791 | 0.040 |
Why?
|
| Gestational Age | 1 | 2023 | 1194 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1378 | 0.040 |
Why?
|
| Heart Atria | 1 | 2020 | 324 | 0.030 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2007 | 3 | 0.030 |
Why?
|
| Ecchymosis | 1 | 2007 | 12 | 0.030 |
Why?
|
| Heart | 1 | 2022 | 650 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 30 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 101 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 63 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 148 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 220 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 92 | 0.030 |
Why?
|
| Polysomnography | 1 | 2017 | 147 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 33 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 2999 | 0.030 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 9703 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2016 | 43 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 165 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 139 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 3252 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 452 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 537 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 122 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 735 | 0.030 |
Why?
|
| United States | 1 | 2020 | 11399 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 85 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 71 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2007 | 492 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 686 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 540 | 0.030 |
Why?
|
| Anemia | 1 | 2007 | 341 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 280 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 30579 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2017 | 346 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2022 | 4987 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 416 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 219 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1867 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 968 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 20494 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12580 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1538 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 10631 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 27867 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2048 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3331 | 0.020 |
Why?
|